Benzinga··Lekha GuptaBDTX Surges on Lung Cancer Data, But Technical Warnings Cloud Outlook
Black Diamond Therapeutics surges on positive lung cancer trial data and earnings beat, but technical weakness signals investor skepticism despite $118.3M cash runway through 2028.
BDTXPhase 2 clinical trialtechnical analysis